Search
for
Sort by
Research
60-90 / 1000+ resultsresearch Direct Vasodilators and Sympatholytic Agents
Direct vasodilators and sympatholytic agents are still useful for certain conditions despite being less common due to side effects and newer drugs.
research finasteride, n.
research Erectile dysfunction from mechanisms to medicines with a focus on the application of topical Minoxidil
research Glyburide blocks the relaxation response to BRL 34915 (cromakalim), minoxidil sulfate and diazoxide in vascular smooth muscle.
research Finasteride plus doxazosin combination tops in BPH
research Finasteride: a 5 alpha-reductase inhibitor.
research A Comparison of Minoxidil and Hydralazine in Non-azotemic Hypertensives
Minoxidil lowers blood pressure more effectively but has more side effects, so try hydralazine first.
research Finasteride Tablets
research Finasteride Tablets
research Adrenolytic and Vasodilator Therapy
New drugs like clonidine and prazosin show promise for treating high blood pressure despite some side effects.
research Finasteride.
research Comparison of Different Alpha-blocker Combinations in Male Hypertensives with Refractory Lower Urinary Tract Symptoms
The doxazosin plus tamsulosin combination improved symptoms effectively with fewer side effects.
research Profound bradycardia after addition of diltiazem to a beta blocker.
Adding diltiazem to a beta blocker can cause dangerously slow heart rates.
research New product intros (finasteride/tadalafil (new combination); sutimlimab; human SARS-CoV-2 recombinant nanoparticle vaccine, adjuvanted with AS03; bupropion hydrochloride/dextromethorphan hydrobromide (new combination))
research O impacto da COVID-19 no ciclo menstrual: uma perspectiva geral
The combination tablet of finasteride and doxazosin works the same as taking each drug separately.
research PD49-03 IS TADALAFIL ASSOCIATED WITH DECREASED RISK OF MAJOR ADVERSE CARDIAC EVENTS OR VENOUS THROMBOEMBOLISM IN MEN WITH LOWER URINARY TRACT SYMPTOMS?
Tadalafil may reduce the risk of major heart events and blood clots in men with urinary symptoms.
research When two plus two must not equal four
Regulatory challenges make developing combination therapies in urology difficult and costly.
research Finasteride 98319‐26‐7
research Finasteride/minoxidil
research Finasteride/minoxidil
research Finasteride/minoxidil
research Kombinationsbehandlung des BPS mit Tamsulosin und Finasterid
research Association of 5-α reductase inhibitors and sexual dysfunction: A RADAR report
Using hair loss drugs finasteride and dutasteride may cause sexual side effects.
research The effect of the combined drug Yuperio with bisoprolol on the dynamics of the heart with dilation of the left chambers, the development of which is due to non-compactness of the myocardium of the left ventricle
Yuperio combined with bisoprolol improves heart function in patients with dilated cardiomyopathy.
research Biopharmaceutical Performance of DiluCap: A Line of Functional Excipients Enhancing Dissolution Profiles of Minoxidil, Finasteride, Melatonin, and Naltrexone.
DiluCap improves how quickly minoxidil and finasteride dissolve and controls the release of melatonin and naltrexone.
research Simultaneous Quantification of Dutasteride and Silodosin Using a Stability-Indicating RP-HPLC Approach
The method accurately and quickly measures silodosin and dutasteride in mixtures.
research Trazodone and chlorpromazine a proposal treatment for syndrome post-finasteride and syndrome of post-selective serotonin reuptake inhibitors (post-SSRI)
Trazodone and Chlorpromazine might help treat sexual dysfunction from finasteride and SSRIs.
research Efficacy and Tolerability of 6-Month Treatment with Tamsulosin Plus the Hexanic Extract of Serenoa repens versus Tamsulosin Plus 5-Alpha-Reductase Inhibitors for Moderate-to-Severe LUTS-BPH Patients: Results of a Paired Matched Clinical Study
Tamsulosin with Serenoa repens is as effective as with 5-alpha-reductase inhibitors but causes fewer side effects.
research Risk assessment of the top 60 drugs for drug-related sexual dysfunction: a disproportion analysis from the Food and Drug Administration adverse event reporting system
Finasteride, dutasteride, and silodosin have the highest risk for causing sexual dysfunction.